Clinical trial
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients…
NCT00193076 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193076 |
|---|---|
| Title | Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer |
| Official title | A Phase II Trial of Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Eli Lilly and Company Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Carboplatin, Trastuzumab |
| Enrollment | 96 |
| Start date | Nov 1, 2003 |
| Primary completion | May 1, 2006 |
| Completion | Oct 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | May 3, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: